ESH. for to to presented updated data everybody morning walk SY-XXXX good we today. joining excited And us you through I'm at that the Nancy. Thanks,
As favorable action, they the rates and of onset response of and CRs combination early patients data complete and important induces deep azacitidine independence profile milestone demonstrate SY-XXXX as transfusion an of a responses. us in durable AML signs that Nancy a tolerability high rapid rates, high of novel mentioned, marked RARA-positive our with for
cut, August to our and in the diagnosed III XX analysis. an patients data Phase enrolled unfit trial contributed of newly AML As safety
six deep patients cytogenetic response. of with showed XX%, a with Additionally, CRs or XX blood CRis. complete XX incomplete for CR rate count CRs seven CRs. were including XX% the RARA-positive responses, being and RARA-positive patients RARA-negative the and patients, data rate In for The recovery was IWG evaluable CRs molecular
the unfit with the treated with was is to rate signs following in single-agent which consistent RARA-positive bone their detectable deep XX% azacitidine. CRi XX%, CRs contrast, We're marrow published patients RARA-negative no in CR in the seeing abnormalities encouraged we're treatment. molecular rates of particularly by AML response By with newly or in patients of observed cytogenetic XX% patients, diagnosed
the of responses with cutoff. to a Importantly, having these our patients of of of types earlier of eight seeing deep three CRs And data lasting some at maturing, still while XXX associated durability we're in typically trial, are more of the responding CRs in the responses. enrolled durable are the duration the data durable months including days, time seven beyond CRs with patients up
were responses after response initial patients at first seen treatment. days RARA-positive Most on the assessment in just XX
of patients XX% the independence. RARA-positive Additionally, or maintained transfusion achieved
is contribute for benefit AML. patients patients which platelet neutrophil normalization measures to really counts Taken for together, speed the objective and with and with transfusion independence clinical of important of that important leukemia, are response, all
this We of distinct AML azacitidine associated these supporting responses the novel-targeted an in outcomes. with encouraged that are that poor patients, RARA-positive patients of enrichment are action in patient population. AML not also for synergistic to with Notably, including SY-XXXX the risk genes seeing typically and our mechanism see groups, we're may combination across responsiveness to responding associated with mutations be
to data patient screened of the clinical Based refractory the are as date, also XXX significant RARA patients data XX% selection. for a biomarker RARA-positive, or AML confirm that our on AML optimal new we trial for approximately representing approximately portion and newly population. from These of believe patients relapsed diagnosed
was analysis. azacitidine grade. azacitidine, alone. neutropenia, combination. majority safety of support toxicities including beyond were well of or generally what and single-agent the Rates low SY-XXXX, with were no SY-XXXX aza, of non-hematologic continue events a to with data profile of with of to is reports Turning comparable adverse clinical in The seen myelosuppression, increased the evidence combination the updated to favorable tolerability tolerated
Enrollment profile with year. report to safety, next in response We cohort the pleased cohort We're nearly cohorts and relapsed/refractory patients the enrollment of durability enrolling of including to of combination, data AML these pace the the follow relapsed/refractory of diagnosed and proof-of-concept further efficacy from RARA-positive to newly the potential expect overall while the patients. characterize complete. plan is
of synergistic RARA-positive with the newly-diagnosed spectrum. across patients disease well treat us relapsed confidence The setting the SY-XXXX that patients, the added the data and or refractory potential to the azacitidine tolerated, highly is strength in gives in combination
to SY-XXXX. to announced development month, now Last SY-XXXX. further we decision the of prioritize SY-XXXX our Moving of and development discontinue
CDKX was on superior molecule inhibition that full of decision based the of the preclinical advantages allow the promise this realize for and an selective rationale to patients. for profile us will to SY-XXXX we Our oral inherent believe
tissues durable mechanism a SY-XXXX with established of proof a in experience conviction clinical in apoptosis and at of higher and in saw patient. inhibition. doses, We reinforced highly refractory patients treated PR Our a CDKX activity in evidence tumor including our
patients the limited expansion in ability adverse patients doses. the at our trial, higher keep As to of we more peri-infusional treated those portion events the
these tracked we not the can inhibition. with levels don't deliver expect sustain if with target to that target these engagement, we SY-XXXX. Importantly, same to lead The believe AEs can issues the peri-infusional is CDKX higher CDKX and concentrations of SY-XXXX promise totality peak which data why of us of see coverage, we of on selective
target dosing As measures, opportunity greater SY-XXXX both an to potency in candidates on also studies, antitumor preclinical of greater better were and tolerability. flexibility models which activity SY-XXXX a greater coverage demonstrating in SY-XXXX provides tested. our wide sustain drug In selectivity, range oral and molecule, outperformed preclinical in with
selectivity we that SY-XXXX at members in ENA best-of-class demonstrated highlight over potential. clinical presented for least related family, CDK closely meeting on its potency CDKX CDKX SY-XXXX and XX,XXX-fold data the preclinical oral new the development. inhibitor selectivity With greater non-covalent The further at greater an than of
regressions tumor overall robust SY-XXXX an at supports growth pathway models preclinical breast, inhibited of these anti-tumor also off dose, below Building work, deep SY-XXXX ovarian with cancer prior dosing sustained and maximum and sustained studied, doses models. were associated which in in that seen demonstrated these was deeper XXX% alterations. and a our responses XX% tolerated activity in and inducing PK the RB daily including of models. lung profile more
with activity Additionally, SY-XXXX models fulvestrant robust ER-positive combination CDKX/X treatment-resistant breast antitumor of in cancer. inhibitor induced also in
activity. the We the of are expect ovarian tumors on types any early program as XXXX, alterations signals to tumor rapidly histology, for of we believe solid breast, and to seeing cancers committed including likely advancing of of we likelihood RB XXXX initiate We're and lung trial the harboring respond focusing to Phase in the increase and as most to quarter I are XXXX, pathway possible. to first that
adapt will us candidates programs to trial to efficiently signals. through we we We've designed key way in drug have forward a allow and early believe you as excellent and we XXXX that beyond. in continue move we clinical dose and these XXXX, year and the believe milestones advance to keeping two look explore updated escalation quickly to more to We next
for results financial that, quarter. With our the over it to I'll to Joe turn review
